LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health at the cellular level, announced the successful conclusion of its ...

LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular ...

"Mike is a strategic leader with a strong track record of translating technological innovation into measurable business ...

Mr. Fife and Mr. Aure will present at approximately 1:00 p.m. Eastern Time on Monday, January 12, 2026. A webcast of their ...

SALT LAKE CITY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the ...

A significant insider buy by Cynthia Latham, Director at Lifevantage (NASDAQ:LFVN), was executed on November 11, and reported in the recent SEC filing. What Happened: A Form 4 filing with the U.S.

SALT LAKE CITY, Oct. 21, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the ...

On Monday, 20 October 2025, LifeVantage Corporation (NASDAQ:LFVN) presented at the LD Micro Main Event XIX Investor Conference, offering insights into its strategic direction. The company highlighted ...

SALT LAKE CITY - LifeVantage Corporation (NASDAQ:LFVN), a company currently trading at $9.56 and showing strong financial health according to InvestingPro analysis, announced Thursday it has completed ...

LifeVantage Corporation reports earnings inline with expectations. Reported EPS is $0.17 EPS, expectations were $0.17. Operator: Good day, ladies and gentlemen. Thank you for standing by. Welcome to ...

Launch delivers innovative business opportunity and top wellness products to Iceland, marking a bold step in European expansion SALT LAKE CITY, July 24, 2025 (GLOBE NEWSWIRE) -- LifeVantage ...

LifeVantage (LFVN) is a mispriced opportunity with potential for >15% IRR, driven by its new GLP-1 product suite and turnaround signals. LFVN's valuation is attractive at ~6x EV/EBITDA and a Fwd PEG ...